Eli Lilly's tirzepatide showed significantly greater weight loss than Novo Nordisk's semaglutide in a 72-week clinical trial ...

Novo Nordisk stock slumped early Monday as the drugmaker was facing a potential hit to revenue from several different ...

Larger studies are needed to confirm the findings, which offer the latest evidence that the medicines can do much more than ...

Eli Lilly and Company announced on Monday detailed results from SURMOUNT-5, a phase 3b open-label clinical trial, evaluating ...

A larger waist circumference is associated with a higher risk of all-cause mortality and decreased life expectancy. Meanwhile ...

Billionaire Chase Coleman Has 68% of His $24.5 Billion Portfolio Invested in 10 Stocks. Here's the Best of the Bunch.

Eli Lilly & Co.’s obesity drug Zepbound helped people trim about two inches more off their waists than Novo Nordisk A/S’s ...

The trends worry health experts, who say the medicines have potential to narrow differences in obesity rates among ...

CVS Caremark decided to stop offering Zepbound in favor of Wegovy for weight loss. It’s the latest example of limits imposed ...

Brigham Buhler, a MAHA influencer and biotech entrepreneur, has Robert F. Kennedy’s ear. But will RFK listen to his call to ...

Some of the bankrupt company’s closest rivals, newer telehealth firms, face a new challenge of their own as federal ...